<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03312582</url>
  </required_header>
  <id_info>
    <org_study_id>FR-17-75</org_study_id>
    <nct_id>NCT03312582</nct_id>
  </id_info>
  <brief_title>Locally Delivered 1% Metformin Gel in Peri-implantitis</brief_title>
  <official_title>Efficacy of Locally Delivered 1% Metformin Gel in the Treatment of Peri-implantitis in Type2 Diabetes Mellitus Patients: A Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Saud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Saud University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of 1% local metformin gel in deep periimplant pockets of
      type 2 diabetes mellitus patients. Half of the participants will receive 1% metformin gel
      with manual debridement while the other half will receive a placebo with manual debridement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metformin is an oral hypoglycemic drug categorized under biguanide and are considered the
      most efficient agents widely used in the treatment of type 2 diabetes mellitus.The general
      clinical benefits observed in therapy with MF seem to be greater than expected. They induce
      osteoblast cells to promote early bone formation through AMP kinase (AMPK) activity.
      Moreover, in a recent in vitro study, MF facilitated in the proliferation of MG63 osteoblast
      like cells. Thus, their action in stimulating bone formation has justified their use in the
      treatment of perimplantitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2015</start_date>
  <completion_date type="Actual">July 24, 2017</completion_date>
  <primary_completion_date type="Actual">August 14, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Marginal bone loss</measure>
    <time_frame>6 months</time_frame>
    <description>Marginal bone loss will be assessed on digital radiographs on calibrated computer screen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peri-implant prpbing depth</measure>
    <time_frame>6 months</time_frame>
    <description>Will be measured with UNC-15 periodontal probe from crest of the gingival margin to the base of the peri-implant probing depth.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Peri-Implantitis</condition>
  <arm_group>
    <arm_group_label>Manual debridement and 1% metformin gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual debridement and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% local metformin gel</intervention_name>
    <description>After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.</description>
    <arm_group_label>Manual debridement and 1% metformin gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Manual debridement and placebo</arm_group_label>
    <other_name>After providing manual debridement in deep peri-implant probing depths, placebo gel will be applied.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus patients.

          -  Patients with peri-implantitis

        Exclusion Criteria:

          -  History of any other systemic diseases

          -  Cigarette smokers

          -  Smokeless tobacco users

          -  Patients who underwent scaling in the last 1 year

          -  Patients who took antibiotics in tje past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2017</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Saud University</investigator_affiliation>
    <investigator_full_name>Zohaib Akram</investigator_full_name>
    <investigator_title>Director, Clinical Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peri-Implantitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

